tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of John Newman, 133 are a BUY (84.71%), 24 are a HOLD (15.29%).
Analyst John Newman, currently employed at CANACCORD, carries an average stock price target met ratio of 36% that have a potential upside of 19.32% achieved within 117 days.
John Newman’s has documented 281 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 23-Jul-2025.
Analyst best performing recommendations are on IMGN (IMMUNOGEN).
The best stock recommendation documented was for ACLX (ARCELLX) at 4/19/2023. The price target of $40 was fulfilled within 5 days with a profit of $4.74 (13.44%) receiving and performance score of 26.89.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$51
$13.3 (35.28%)
$71
1 months 29 days ago
(22-Jul-2025)
6/9 (66.67%)
$11.34 (28.59%)
477
Buy
$57
$19.3 (51.19%)
$55
9 months 10 days ago
(10-Dec-2024)
5/6 (83.33%)
$10.98 (23.86%)
84
Buy
$51
$13.3 (35.28%)
11 months 10 days ago
(10-Oct-2024)
1/1 (100%)
$9.18 (21.95%)
27
Hold
$56
$18.3 (48.54%)
$61
11 months 24 days ago
(27-Sep-2024)
10/13 (76.92%)
$10.39 (22.78%)
223
Hold
$46
$8.3 (22.02%)
$30
1 years 3 months 7 days ago
(13-Jun-2024)
4/4 (100%)
$-0.77 (-1.65%)
169
Which stock is John Newman is most bullish on?
What Year was the first public recommendation made by John Newman?
